SpulsP.I., HadiS., RiveraL., LebwohlM.Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatolog Treat.2003; 14 Suppl 2: 21–5.
2.
AshurstP.J.C.Relapsing pustular eruptions of the hands and feet. Br J Dermatol.1958; 76: 169.
HradilE., GentzC.F., MatilainenT., SauzenL., UdenA.Skeletal involvement in pustulosis palmoplantaris with special reference to sternocostoclavicular joint. Acta Derm Venereol.1988; 68: 65–73.
5.
JurikA.G., TernowitzT.Frequency of skeletal disease: arthro-osteitis in patients with pustulosis palmoplantaris. J Am Acad Dermatol.1988; 18: 666–71.
6.
WalshS.R., ShearN.H.Psoriasis and the new biologic agents: interrupting a T-AP dance. CMAJ.2004 Jun 22; 170(13): 1933–41.
7.
RichS.J., Bello-QuinteroC.E.Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm.2004 Jul-Aug; 10(4): 318–25.
8.
FinlayA.Y., SalekM.S., HaneyJ. for the Alefacept Clinical Study Group. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology.2003; 206: 307–15.
9.
FeldmanS.R., MenterA., KooJ.Y.Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol.2004; 150: 317–26.
10.
American College of Rheumatology. FDA meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part II: CHF, infection and other safety issues. Available at http://www.rheumatology.org/publications/hotline/0803chf.asp?aud=mem. Accessed Dec. 30, 2004.
11.
PatelT., GordonK.B.Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther.2004; 17(5): 427–31.
12.
ChewA.L., BennettA., SmithC.H., BarkerJ., KirkhamB.Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol.2004 Aug; 151(2): 492–6.
